D. Grazziotin-Soares, J.-P. Lotz

Oncologie, Vol.21, No.1, pp. 69-72, 2019, DOI:10.3166/onco-2019-0030

Abstract Several studies have shown an association between Epstein-Barr virus (EBV) infection and some human cancers such as a subgroup of gastric carcinomas. The oncogenic potential of EBV has been widely explored but the exact processes conducting carcinogenesis are not yet fully understood. EBV-encoded viral proteins are known to deregulate the DNA damage response (DDR) signaling pathways. DDR inactivation leads to genomic instability and promote cellular transformation to generate malignant cells. In a recently published article in Nature Medicine, a molecular characterization of tumor tissue and circulating tumor DNA (cDNA) from non-selected patients with metastatic gastric cancer treated with pembrolizumab was… More >

Yuan Liu^1,2,#, Yun Jia³, Bing Zhang², Anwen Liu^1,*

Oncologie, Vol.23, No.1, pp. 61-72, 2021, DOI:10.32604/Oncologie.2021.015906

Abstract Gastric cancer (GC) is the most common digestive system malignant tumor and second most common cause of cancer-related death. Even for the early gastric cancer, after radical operation, perioperative and postoperative chemotherapy the recurrence and metastasis are also high. 5-year overall survival of all GC patients is only 10–15%. Chemo-resistance still poses a major obstacle to successful treatment of GC. The aberrant expression of TUG1 (Taurine Upregulated Gene 1) was closely related to chemo-resistance and metastasis in many cancers. Here we over-expressed TUG1 in GC cell line SGC-7901 and MGC-803. We compared the migration ability and sensitivity of cisplatin (CDDP),… More >

Pierre-Guillaume Poureau^1,2,*, Jean-Philippe Metges²

Oncologie, Vol.23, No.1, pp. 47-59, 2021, DOI:10.32604/Oncologie.2021.15525

Abstract Immunotherapy for digestive cancers is booming and for the first time an immune checkpoint inhibitor has been granted marketing authorization for the treatment of digestive cancer. In order to better understand the mecanism of action of these treatments, their adverse events and the escape mecansim, it is necessary to know the fundamentals of cancer immunology. The innate and adaptive immune system allows the elimination of cancer cells by direct non-specific cytotoxicity (Natural Killer cells), by the development of an adaptive cell-mediated response (dendritic cells becoming antigen presenting cells, allowing the differentiation of lymphocytes naive in CD4 and CD8 T lymphocytes)… More >

Fei Han¹, Jianghong Qu², Fengyue Li¹, Dapeng Zhang³, Jiangming Qu⁴, Guanghua Li^5,*

Oncologie, Vol.23, No.1, pp. 131-140, 2021, DOI:10.32604/Oncologie.2021.014153

Abstract Aim: This study aims to explore the role of serum long non-coding RNA (lncRNA) colon cancer-associated transcript 2 (CCAT2) as a diagnostic marker for gastric cancer (GC). Methods: We recruited 76 patients with GC admitted to our hospital (the observation group, OG) and 83 healthy volunteers undergoing physical examinations during the same period (the control group, CG). CCAT2 expression was tested and its correlation with clinicopathological characteristics of GC was analyzed. We also explored the value of CCAT2 in assessing the treatment efficacy, predicting the fatality, and evaluating the prognosis of patients. Results: We detected higher CCAT2 levels in OG… More >

PING YANG, LIJUAN YUAN, SHUJIA PENG, YANMING DONG, LIN YANG, XI’E HU, GUOQIANG BAO^*

BIOCELL, Vol.45, No.1, pp. 103-108, 2021, DOI:10.32604/biocell.2021.011220

Abstract This study aimed to evaluate the association between the CLEC3A gene polymorphisms (rs2735401/rs2293776/ rs2072665) and the gastric cancer risk in the Northwestern Chinese population. A hospital-based case-control study was conducted on 681 cases and 756 healthy controls. Odds ratio (OR) and 95% confidence intervals (CI) were applied to evaluate the association of the CLEC3A polymorphisms on gastric cancer risk. We found that there was no significant association between the CLEC3A polymorphisms and gastric cancer susceptibility, which was detected in the main analysis or stratification analyses of age, gender, and clinical stages. Our findings verified that the CLEC3A polymorphisms are not… More >

Tiangen WU¹, Tianhao BAO^2,3, Daoming LIANG^1,*, Lin WANG^4,*

BIOCELL, Vol.43, No.4, pp. 293-298, 2019, DOI:10.32604/biocell.2019.07841

Abstract Circulating tumor cells (CTCs) are crucial to tumor metastasis, and they usually undergo epithelial– mesenchymal transition (EMT) in order to disseminate from the primary tumor. However, very little is currently known about the relationship between EMT and malignant phenotypes of CTCs in the context of gastric cancer. Therefore, this study aimed to investigate the contribution of EMT to malignant phenotypes of CTCs derived from gastric cancer cells. We xenografted MKN28 gastric cancer cells pretreated with transforming growth factor-beta 1 (TGFβ-1) into nude mice by intravenous injection. Next, we isolated CTCs from the blood of nude mice by gradient centrifugation and… More >

ELEONIDAS MOURA LIMA^1,2, MARIANA FERREIRA LEAL³, MARÍLIA DE ARRUDA CARDOSO SMITH³, ROMMEL RODRÍGUEZ BURBANO⁴, PAULO PIMENTEL DE ASSUMPÇÃO⁵, MARIA JOSE BELLO⁶, JUAN ANTONIO REY⁶, FRANCINALDO FERREIRA DE LIMA⁷, CACILDA CASARTELLI²

BIOCELL, Vol.32, No.3, pp. 237-243, 2008, DOI:10.32604/biocell.2008.32.237

Abstract Gastric cancer is one of the most common malignancies. DNA methylation is implicated in DNA mismatch repair genes deficiency. In the present study, we evaluated the methylation status of MLH1, MSH2, MSH6 and PMS2 in 20 diffuse- and 26 intestinal-type gastric cancer samples and 20 normal gastric mucosal of gastric cancer patients from Northern Brazil. We found that none of the nonneoplastic samples showed methylation of any gene promoter and 50% of gastric cancer samples showed at least one methylated gene promoter. Methylation frequencies of MLH1, MSH2, MSH6 and PMS2 promoter were 21.74%, 17.39%, 0% and 28.26% respectively in gastric… More >